Dacarbazine
Back to searchMolecule Structure
Scientific Name
Dacarbazine
Description of the Drug
Dacarbazine is an antineoplastic agent used to treat malignant melanoma and Hodgkin’s disease.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00851
http://www.drugbank.ca/drugs/DB00851
Brand Name(s)
Dacarbazine, Dtic-dome
Company Owner(s)
Fresenius Kabi Usa Llc, Hospira Inc, Abraxis Pharmaceutical Products, Bayer Healthcare Pharmaceuticals Inc, Teva Pharmaceuticals Usa, Hikma Pharmaceuticals Usa Inc
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| DNA | NUCLEIC-ACID | INHIBITOR | CHEMBL2311221 |
Clinical Trial(s)
Unichem Links
| SureChEMBL | SCHEMBL5560 |
| DrugBank | DB00851 |
| PubChem: Thomson Pharma | 15147351 |
| PubChem | 135398738 |
| Mcule | MCULE-2865817662 |
| Nikkaji | J2.212H |
| BindingDB | 50238687 |
| DrugCentral | 773 |
| ChemicalBook | CB7710656 |
| rxnorm | DACARBAZINE |
| KEGG Ligand | C06936 |
| ChEBI | 177836 |
| ZINC | ZINC000100019007 |
